Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medi-Physics full-scale launch of cardiac imaging agent Myoview planned for April.

This article was originally published in The Gray Sheet

Executive Summary

MEDI-PHYSICS' MYOVIEW SCINTIGRAPHIC CARDIAC IMAGING AGENT Full-scall launch is slated for April, the company says. Approved by FDA Feb. 9, Myoview (technetium Tc99m tetrofosmin) is indicated for "scintigraphic imaging of the myocardium following separate administrations under exercise and resting conditions." The product is "useful in the delineation of regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium," labeling states.

You may also be interested in...



Nycomed Amersham's Myoview Approvable For Rx Stress Testing Indication

Nycomed Amersham Imaging says it has received word from FDA that its Myoview kit for the preparation of technetium Tc-99m tetrofosmin is approvable for use with pharmacologic stress agents.

Novartis Targets Ten Indications For Cosentyx

The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.

UsernamePublicRestriction

Register

MT005503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel